Stock Events

Stock Events

Antibe Therapeutics 

$0.22
33
+$0+0% Wednesday 20:00

Statistics

Day High
0.22
Day Low
0.22
52W High
0.22
52W Low
0.22
Volume
17,935
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

13FebExpected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
-0.17
-0.14
-0.12
-0.09
Expected EPS
-0.09
Actual EPS
N/A

Financials

-278.73%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
5.17MRevenue
-14.4MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATBPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the inflammation and pain management sector, directly challenging Antibe's core market with its range of anti-inflammatory and pain relief medications.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio of drugs that address similar therapeutic areas as Antibe, including pain management and inflammation, making it a direct competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the same space as Antibe's, particularly in the areas of pain relief and anti-inflammatory treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis provides a wide array of medications, including those for pain and inflammation, directly competing with Antibe Therapeutics in these therapeutic areas.
Merck
MRK
Mkt Cap214.76B
Merck operates in various therapeutic areas, including pain management and inflammation, offering competitive products to those of Antibe Therapeutics.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a diverse pharmaceutical portfolio that includes treatments for pain and inflammation, positioning it as a competitor to Antibe.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers several drugs that target the same therapeutic areas as Antibe, making it a competitor in the market for anti-inflammatory and pain management solutions.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on innovative therapeutics, including those for inflammation and pain, which competes with Antibe's research and product offerings.
Biogen
BIIB
Mkt Cap22.63B
Biogen's focus on novel therapies, including those for inflammatory diseases, places it in direct competition with Antibe Therapeutics.
Sanofi
SNY
Mkt Cap124.45B
Sanofi has a broad portfolio that includes treatments for pain and inflammation, directly competing with Antibe in these therapeutic areas.

About

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
Show more...
CEO
Mr. Daniel Marcel Legault J.D., L.L.B.
Employees
11
Country
CA

Listings

0 Comments

Share your thoughts

FAQ

What is Antibe Therapeutics stock price today?▼
The current price of ATBPF is $0.22 USD — it has increased by +0% in the past 24 hours. Watch Antibe Therapeutics stock price performance more closely on the chart.
What is Antibe Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Antibe Therapeutics stocks are traded under the ticker ATBPF.
What is Antibe Therapeutics revenue for the last year?▼
Antibe Therapeutics revenue for the last year amounts to 5.17M USD.
What is Antibe Therapeutics net income for the last year?▼
ATBPF net income for the last year is -14.4M USD.
How many employees does Antibe Therapeutics have?▼
As of April 02, 2026, the company has 11 employees.
In which sector is Antibe Therapeutics located?▼
Antibe Therapeutics operates in the Health Care sector.
When did Antibe Therapeutics complete a stock split?▼
The last stock split for Antibe Therapeutics was on December 01, 2020 with a ratio of 1:10.
Where is Antibe Therapeutics headquartered?▼
Antibe Therapeutics is headquartered in Toronto, CA.